Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617002874> ?p ?o ?g. }
- W2617002874 endingPage "44311" @default.
- W2617002874 startingPage "44295" @default.
- W2617002874 abstract "Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients with PDAC have mutations in KRAS, which unfortunately remains an ineffectual target. Our strategy here is to target KRAS downstream effectors PI3K and mTOR. In this study, we investigated the antitumor efficacy of the novel PI3K and mTOR dual inhibitor VS-5584 in PDAC. Our data shows that PI3K/mTOR dual inhibition causes ERK activation in all tested PDAC cell lines. Although the MEK inhibitor GSK1120212 could abrogate VS-5584-induced ERK activation, it did not substantially enhance cell death in all the cell lines tested. However, combination with ERK inhibitor SCH772984 not only mitigated VS-5584-induced ERK activation but also enhanced VS-5584-induced cell death. In a xenograft model of PDAC, we observed 28% and 44% tumor inhibition for individual treatment with VS-5584 and SCH772984, respectively, while the combined treatment showed superior tumor inhibition (80%) compared to vehicle control treatment. Our findings support the clinical development of VS-5584 and ERK inhibitor combination for PDAC treatment." @default.
- W2617002874 created "2017-06-05" @default.
- W2617002874 creator A5000948146 @default.
- W2617002874 creator A5008374158 @default.
- W2617002874 creator A5011312785 @default.
- W2617002874 creator A5018331471 @default.
- W2617002874 creator A5018943067 @default.
- W2617002874 creator A5026401594 @default.
- W2617002874 creator A5041282750 @default.
- W2617002874 creator A5054527442 @default.
- W2617002874 creator A5056962753 @default.
- W2617002874 creator A5061036650 @default.
- W2617002874 creator A5073948405 @default.
- W2617002874 creator A5084102458 @default.
- W2617002874 creator A5085956632 @default.
- W2617002874 date "2017-05-15" @default.
- W2617002874 modified "2023-10-18" @default.
- W2617002874 title "Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer" @default.
- W2617002874 cites W1509939948 @default.
- W2617002874 cites W1596038553 @default.
- W2617002874 cites W1848470479 @default.
- W2617002874 cites W1931508686 @default.
- W2617002874 cites W1968812902 @default.
- W2617002874 cites W1971727526 @default.
- W2617002874 cites W1975931552 @default.
- W2617002874 cites W1990824742 @default.
- W2617002874 cites W1994726128 @default.
- W2617002874 cites W2004800205 @default.
- W2617002874 cites W2025909040 @default.
- W2617002874 cites W2029376990 @default.
- W2617002874 cites W2032909215 @default.
- W2617002874 cites W2041811289 @default.
- W2617002874 cites W2050573392 @default.
- W2617002874 cites W2054917860 @default.
- W2617002874 cites W2057370954 @default.
- W2617002874 cites W2061772840 @default.
- W2617002874 cites W2067019627 @default.
- W2617002874 cites W2082246284 @default.
- W2617002874 cites W2103562758 @default.
- W2617002874 cites W2112296880 @default.
- W2617002874 cites W2115099563 @default.
- W2617002874 cites W2118993510 @default.
- W2617002874 cites W2126783165 @default.
- W2617002874 cites W2129915570 @default.
- W2617002874 cites W2140277032 @default.
- W2617002874 cites W2140936582 @default.
- W2617002874 cites W2146414563 @default.
- W2617002874 cites W2148823465 @default.
- W2617002874 cites W2155789124 @default.
- W2617002874 cites W2157983986 @default.
- W2617002874 cites W2165480504 @default.
- W2617002874 cites W2165864070 @default.
- W2617002874 cites W2167789626 @default.
- W2617002874 cites W2201713764 @default.
- W2617002874 cites W2211890826 @default.
- W2617002874 cites W2235523093 @default.
- W2617002874 cites W2347187110 @default.
- W2617002874 cites W4254047100 @default.
- W2617002874 doi "https://doi.org/10.18632/oncotarget.17869" @default.
- W2617002874 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5546481" @default.
- W2617002874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28574828" @default.
- W2617002874 hasPublicationYear "2017" @default.
- W2617002874 type Work @default.
- W2617002874 sameAs 2617002874 @default.
- W2617002874 citedByCount "23" @default.
- W2617002874 countsByYear W26170028742017 @default.
- W2617002874 countsByYear W26170028742018 @default.
- W2617002874 countsByYear W26170028742019 @default.
- W2617002874 countsByYear W26170028742020 @default.
- W2617002874 countsByYear W26170028742021 @default.
- W2617002874 countsByYear W26170028742022 @default.
- W2617002874 crossrefType "journal-article" @default.
- W2617002874 hasAuthorship W2617002874A5000948146 @default.
- W2617002874 hasAuthorship W2617002874A5008374158 @default.
- W2617002874 hasAuthorship W2617002874A5011312785 @default.
- W2617002874 hasAuthorship W2617002874A5018331471 @default.
- W2617002874 hasAuthorship W2617002874A5018943067 @default.
- W2617002874 hasAuthorship W2617002874A5026401594 @default.
- W2617002874 hasAuthorship W2617002874A5041282750 @default.
- W2617002874 hasAuthorship W2617002874A5054527442 @default.
- W2617002874 hasAuthorship W2617002874A5056962753 @default.
- W2617002874 hasAuthorship W2617002874A5061036650 @default.
- W2617002874 hasAuthorship W2617002874A5073948405 @default.
- W2617002874 hasAuthorship W2617002874A5084102458 @default.
- W2617002874 hasAuthorship W2617002874A5085956632 @default.
- W2617002874 hasBestOaLocation W26170028741 @default.
- W2617002874 hasConcept C121608353 @default.
- W2617002874 hasConcept C126322002 @default.
- W2617002874 hasConcept C183713625 @default.
- W2617002874 hasConcept C184235292 @default.
- W2617002874 hasConcept C185592680 @default.
- W2617002874 hasConcept C190283241 @default.
- W2617002874 hasConcept C2780210213 @default.
- W2617002874 hasConcept C2781187634 @default.
- W2617002874 hasConcept C2781249067 @default.
- W2617002874 hasConcept C502942594 @default.
- W2617002874 hasConcept C526805850 @default.
- W2617002874 hasConcept C55493867 @default.